NDA 215842 · Novo
Rivfloza
Nedosiran Sodium · Injection
NovelBreakthrough therapyOrphanCDER novel approval, Sep 29, 2023: To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function
Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 29, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 1 recruiting
FAERS reports
12
8 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2025.
RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 [see Clinical Pharmacology ( 12.3 )], Clinical Studies ( 14.1 )]. RIVFLOZA is an LDHA -directed small interfering RNA indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 . ( 1 )
Mechanism: Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR) to deliver nedosiran to hepatocytes. Nedosiran reduces levels of hepatic lactate dehydrogenase (LDH) via the degradation of LDHA messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. The reduction of hepatic LDH by nedosiran reduces the production of oxalate by the liver, thereby reducing subsequent oxalate burden.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2025 Supplement 2 · Efficacy OrphanLabelLetter
- Sep 29, 2023 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
3 products under this application
- RIVFLOZA · NEDOSIRAN SODIUM EQ 160MG BASE/ML (EQ 160MG BASE/ML) · SOLUTION, INJECTION · Prescription
- RIVFLOZA · NEDOSIRAN SODIUM EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML) · SOLUTION, INJECTION · Prescription
- RIVFLOZA · NEDOSIRAN SODIUM EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML) · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nedosiran" as an intervention, any sponsor and status, largest first.
- Long Term Extension Study in Patients With Primary HyperoxaluriaPivotal-lookingActive, not recruiting
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
NCT04042402 · 75 participants (planned) · Start Jul 9, 2019 · Primary completion Apr 1, 2030
Drug: DCR-PHXC · For: Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases and 3 more
Sites: San Francisco, California; Boston, Massachusetts; Rochester, Minnesota · 23 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03847909 · 35 participants · Start Oct 28, 2019 · Primary completion Jun 21, 2021
Drug: DCR-PHXC; Sterile Normal Saline (0.9% NaCl) · For: Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases and 2 more
Sites: San Francisco, California; Boston, Massachusetts; Rochester, Minnesota · 28 sites in all
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
NCT04580420 · 28 participants (planned) · Start Apr 15, 2021 · Primary completion Dec 30, 2031
Drug: DCR-PHXC · For: Primary Hyperoxaluria Type 1; End Stage Renal Disease
Sites: San Francisco, California; Boston, Massachusetts; Rochester, Minnesota · 18 sites in all
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
NCT05001269 · 27 participants · Start Feb 22, 2022 · Primary completion Feb 5, 2025
Drug: nedosiran · For: Primary Hyperoxaluria; Primary Hyperoxaluria Type 1; Primary Hyperoxaluria Type 2 and 1 more
Sites: Rochester, Minnesota; Hamilton, Canada; Bonn, Germany · 13 sites in all
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
NCT04555486 · 6 participants · Start Sep 14, 2020 · Primary completion Sep 7, 2021
Drug: DCR-PHXC; Sterile Normal Saline (0.9% NaCl) · For: Primary Hyperoxaluria Type 3
Sites: Boston, Massachusetts; Rochester, Minnesota; New York, New York · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urine oxalate increased3
- inappropriate schedule of product administration2
- rash2
- abdominal pain1
- amenorrhoea1
- bone pain1
- death1
- dehydration1
- diabetes mellitus1
- drug ineffective1
- febrile infection1
- haemoglobin increased1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 3 |
| 2025 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Baum MA, Langman C, Cochat P, et al. · Kidney Int 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Goldfarb DS, Lieske JC, Groothoff J, et al. · Urolithiasis 2023 · Clinical Trial, Phase I
- Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).
Sas DJ, Bakkaloglu SA, Belostotsky V, et al. · Pediatr Nephrol 2025 · Clinical Trial, Phase II, Multicenter Study
- Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Hoppe B, Koch A, Cochat P, et al. · Kidney Int 2022 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Novo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.